The plasma proteins GSN, F2, CRTAC1, and HP are associated with multigenerational health, longevity, and resilience
Year: 2026
Type: article
Study design: Observational Study
Abstract: Background The risk of chronic diseases and multimorbidity increases with age, yet, individuals of the same age can strongly differ in healthspan, ranging from early manifestation of age-related disease to robust health into very old age. Plasma biomarkers, including metabolites and proteins, can capture intrinsic health status, thereby providing insights into the nature of this variation. These biomarkers have been widely explored to understand chronic and early disease risk, but less so for disease resilience in mid- and late-life survival (i.e. after 90 years), or for multigenerational longevity. Methods We quantified 326 plasma proteins using data-independent mass spectrometry in two generations of the Leiden Longevity Study cohort: F1 nonagenarian siblings (late-life; age ≥89; N=852) and F2 offspring and their partners (mid-life; age 30–80; N=2282). Baseline plasma protein levels were tested for association with mid- and late-life survival, with up to 22 years of follow-up, and cardiometabolic healthspan, with up to 16 years of follow-up. By comparing F2 offspring and partners, we tested for plasma proteins associating with familial longevity. Findings Four proteins: gelsolin (GSN), prothrombin (F2), cartilage acidic protein 1 (CRTAC1), and haptoglobin (HP), consistently associated with increased mid- and late-life survival, prolonged cardiometabolic healthspan, and familial longevity; representing overall resilience. Moreover, six proteins: serum amyloid P-component (APCS), complement C7 (C7), ficolin 2 (FCN2), haptoglobin-related protein (HPR), polymeric immunoglobulin receptor (PIGR), and GSN, associated with mortality independent of MetaboHealth, a well-established metabolomics-based mortality score. Interpretation We identified GSN, F2, CRTAC1, and HP as promising candidate indicators of healthy ageing and resilience, meriting further study. Funding ZonMw, LUF, BBMRI-NL, VOILA, DFG, Jörg Bernards-Stiftung, Köln Fortune, and CECAD.
Source: EBioMedicine
Language: English
Subfield: Aging
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $5,780
OpenAlex ID: W7128429882
